Know Cancer

forgot password

AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer

Phase 1
18 Years
Open (Enrolling)
Pancreatic Adenocarcinoma, Pancreatic Cancer

Thank you

Trial Information

AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer

The AdV-tk vector is injected into the tumor or tumor bed at the time of biopsy or standard
tumor surgery after which valacyclovir pills are taken for 14 days. Two courses of AdV-tk,
each followed by valacyclovir, are given as adjuvant to standard of care therapies (surgery
and/or chemoradiation) which have been shown to work cooperatively with AdV-tk to kill tumor
cells. Arm A is for resectable tumors in which the first course is given prior to surgery
and the second is at the time of surgery. Arm B is for locally advanced disease in which
both AdV-tk injections are administered by needle injection into the tumor before and during
chemoradiation. The hypothesis is that this combination therapy can be safely delivered and
will lead to improvement in the clinical outcome for patients with pancreatic cancer.

Inclusion Criteria:

- Must have presumed pancreatic adenocarcinoma based on clinical and radiologic
evaluation with identifiable tumor accessible for injection (pathologic diagnosis of
pancreatic adenocarcinoma must be made prior to AdV-tk injection

- For Arm A, resectable disease. Arm B for locally advanced disease has completed

- Performance status must be ECOG 0-2

- SGOT (AST)<3x upper limit of normal

- Serum creatinine<2mg/dl and calculated creatinine clearance >10ml/min

- Platelets>100,000/mm3 and WBC>3000/mm3 and ANC>1500/mm3

- Must give study specific informed consent prior to enrollment

Exclusion Criteria:

- Primary hepatic dysfunction including active hepatitis but not to exclude patients
due to obstructive jaundice. If obstructive jaundice is clinically significant,
bilirubin should be stable or decreasing prior to enrollment.

- Evidence of clinically significant pancreatitis as determined by the investigator.

- Patients on corticosteroids or other immunosuppressive drugs

- Known HIV+ patients

- Patients with acute infections (viral, bacterial or fungal infections requiring

- Pregnant or breast-feeding patients. Female patients of childbearing age must have
negative serum or urine pregnancy test within 1 week of beginning therapy

- Evidence of distant metastatic disease at the time of enrollment or other malignancy
(except squamous or basal cell skin cancers) and no prior abdominal radiation therapy
or prior treatment for pancreatic cancer

- Other serious co-morbid illness or compromised organ function

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety based on symptoms and laboratory abnormalities not expected from standard of care treatments or natural history of the disease process. Toxicity grading uses NCI CTC version 3. Dose limiting toxicity is specifically defined in the protocol.

Outcome Time Frame:

2 months

Safety Issue:


Principal Investigator

Mark Bloomston, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ohio State University


United States: Food and Drug Administration

Study ID:




Start Date:

November 2007

Completion Date:

Related Keywords:

  • Pancreatic Adenocarcinoma
  • Pancreatic Cancer
  • Immunotherapy
  • Gene Therapy
  • Cytotoxicity
  • Tumor vaccine
  • Radiation
  • Surgery
  • Chemoradiation
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Pancreatic Neoplasms



City of Hope Medical Center Duarte, California  91010
The Ohio State University Columbus, Ohio  43210
Scripps Green Hospital/Scripps Cancer Center La Jolla, California  92037